Exelixis (NASDAQ:EXEL) Director Jack Wyszomierski Sells 99,574 Shares

by · The Cerbat Gem

Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) Director Jack Wyszomierski sold 99,574 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $44.01, for a total value of $4,382,251.74. Following the sale, the director directly owned 279,942 shares of the company’s stock, valued at $12,320,247.42. The trade was a 26.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Exelixis Stock Performance

Shares of EXEL traded down $0.53 during mid-day trading on Friday, hitting $43.63. The company’s stock had a trading volume of 1,955,827 shares, compared to its average volume of 2,654,993. The stock’s 50-day moving average is $43.88 and its two-hundred day moving average is $41.20. The firm has a market capitalization of $11.33 billion, a PE ratio of 15.75, a price-to-earnings-growth ratio of 0.99 and a beta of 0.42. Exelixis, Inc. has a one year low of $32.38 and a one year high of $49.62.

Exelixis (NASDAQ:EXEL – Get Free Report) last issued its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.20. The firm had revenue of $598.66 million for the quarter, compared to analyst estimates of $609.17 million. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The company’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.55 earnings per share. Analysts expect that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Wall Street Zen cut shares of Exelixis from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. Morgan Stanley boosted their price objective on shares of Exelixis from $48.00 to $49.00 and gave the stock an “equal weight” rating in a research note on Monday, February 2nd. UBS Group set a $41.00 target price on shares of Exelixis in a research note on Monday, January 5th. Zacks Research raised Exelixis from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. Finally, Oppenheimer reaffirmed a “market perform” rating and issued a $36.00 price objective on shares of Exelixis in a research report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $47.11.

Read Our Latest Analysis on EXEL

Institutional Trading of Exelixis

A number of institutional investors and hedge funds have recently made changes to their positions in EXEL. Police & Firemen s Retirement System of New Jersey grew its position in shares of Exelixis by 0.3% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 102,581 shares of the biotechnology company’s stock valued at $4,521,000 after buying an additional 274 shares during the last quarter. Richardson Financial Services Inc. raised its position in shares of Exelixis by 95.1% during the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 292 shares during the period. RHS Financial LLC lifted its stake in shares of Exelixis by 2.4% in the fourth quarter. RHS Financial LLC now owns 12,619 shares of the biotechnology company’s stock valued at $553,000 after buying an additional 293 shares in the last quarter. Meeder Advisory Services Inc. boosted its stake in Exelixis by 5.8% during the 4th quarter. Meeder Advisory Services Inc. now owns 5,406 shares of the biotechnology company’s stock valued at $237,000 after purchasing an additional 298 shares during the last quarter. Finally, Cim LLC grew its holdings in Exelixis by 0.9% during the third quarter. Cim LLC now owns 35,397 shares of the biotechnology company’s stock worth $1,462,000 after buying an additional 305 shares in the last quarter. Institutional investors own 85.27% of the company’s stock.

About Exelixis

(Get Free Report)

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.

Read More